drugset / Trial / NCT00360698
Insulin Glulisine in Type 2 Diabetic Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.
Timeline
- Start
- 2006-07
- Primary completion
- 2008-08
- Completion
- 2008-08
Outcome
Met primary endpoint
registry analysis (superiority or other test); Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride; p = 0.0499; Risk Difference (RD) 13.68 (95% CI 0.01 to 28.37); Chi-squared NCT00360698 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin glulisine | Protein / enzyme biologic | — | — |
| Subject | insulin glargine | Protein / enzyme biologic | — | — |
| Background | Glimepiride | Small molecule | — | — |
| Background | Metformin | Small molecule | — | — |